Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023
May 04, 2023 at 04:04 pm EDT
Share
Puma Biotechnology, Inc. provides earnings guidance for the second quarter and full year 2023. For the second quarter, the company expects Net Product Revenue of $47 - $50 million, Royalty Revenue of $2 - $3 million and Net Income of $0 - $1.5 million.
For the full year, the company expects Net Product Revenue of $205 - $210 million, Royalty Revenue of $25 - $30 million and Net Income of $20 - $24 million.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
